| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Exposure Prophylaxis | 9 | 2024 | 23 | 6.180 |
Why?
|
| Anti-HIV Agents | 11 | 2024 | 153 | 6.130 |
Why?
|
| HIV Infections | 17 | 2024 | 913 | 5.850 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 70 | 4.340 |
Why?
|
| Substance-Related Disorders | 9 | 2024 | 682 | 3.760 |
Why?
|
| Toxicology | 8 | 2020 | 33 | 3.500 |
Why?
|
| Medication Adherence | 13 | 2024 | 239 | 3.120 |
Why?
|
| Music Therapy | 4 | 2024 | 17 | 2.860 |
Why?
|
| Analgesics, Opioid | 14 | 2024 | 483 | 2.840 |
Why?
|
| Emergency Service, Hospital | 16 | 2024 | 1021 | 2.630 |
Why?
|
| Biosensing Techniques | 6 | 2022 | 113 | 2.300 |
Why?
|
| Homosexuality, Male | 9 | 2024 | 38 | 2.240 |
Why?
|
| Opioid-Related Disorders | 8 | 2024 | 456 | 2.220 |
Why?
|
| Medical Marijuana | 10 | 2024 | 18 | 1.980 |
Why?
|
| Music | 5 | 2024 | 78 | 1.940 |
Why?
|
| Chronic Pain | 5 | 2024 | 134 | 1.820 |
Why?
|
| Social Media | 4 | 2020 | 117 | 1.780 |
Why?
|
| Water Pollutants, Chemical | 3 | 2021 | 35 | 1.570 |
Why?
|
| Smartphone | 5 | 2024 | 64 | 1.520 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 450 | 1.500 |
Why?
|
| Drug Overdose | 5 | 2022 | 126 | 1.490 |
Why?
|
| Humans | 95 | 2024 | 59356 | 1.470 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 62 | 1.450 |
Why?
|
| Adult | 39 | 2024 | 15669 | 1.380 |
Why?
|
| Acute Pain | 3 | 2024 | 17 | 1.350 |
Why?
|
| Pain | 5 | 2023 | 396 | 1.320 |
Why?
|
| Information Dissemination | 3 | 2020 | 112 | 1.320 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 140 | 1.320 |
Why?
|
| Robotics | 2 | 2021 | 69 | 1.300 |
Why?
|
| Telemedicine | 4 | 2024 | 307 | 1.270 |
Why?
|
| Male | 43 | 2024 | 27738 | 1.240 |
Why?
|
| Hospitals | 3 | 2021 | 375 | 1.200 |
Why?
|
| Wireless Technology | 2 | 2020 | 18 | 1.170 |
Why?
|
| Substance Abuse Detection | 4 | 2024 | 44 | 1.160 |
Why?
|
| Oxycodone | 2 | 2017 | 30 | 1.110 |
Why?
|
| Neoplasms | 11 | 2024 | 1240 | 1.090 |
Why?
|
| Pandemics | 11 | 2024 | 615 | 1.050 |
Why?
|
| Fractures, Bone | 2 | 2017 | 136 | 1.020 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 408 | 1.000 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 117 | 0.970 |
Why?
|
| Emtricitabine | 4 | 2024 | 8 | 0.970 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 192 | 0.970 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 205 | 0.960 |
Why?
|
| Cannabis | 5 | 2023 | 49 | 0.960 |
Why?
|
| Narcotic Antagonists | 4 | 2020 | 121 | 0.930 |
Why?
|
| Nociception | 2 | 2020 | 9 | 0.890 |
Why?
|
| Naloxone | 4 | 2020 | 57 | 0.890 |
Why?
|
| Hydroxychloroquine | 2 | 2022 | 19 | 0.880 |
Why?
|
| Calcium Channel Blockers | 1 | 2024 | 56 | 0.880 |
Why?
|
| Scholarly Communication | 2 | 2020 | 3 | 0.850 |
Why?
|
| Mentors | 3 | 2023 | 116 | 0.820 |
Why?
|
| Middle Aged | 23 | 2024 | 16317 | 0.780 |
Why?
|
| Referral and Consultation | 2 | 2015 | 398 | 0.770 |
Why?
|
| Female | 33 | 2024 | 30704 | 0.760 |
Why?
|
| Internet | 5 | 2018 | 449 | 0.740 |
Why?
|
| Research Personnel | 3 | 2023 | 92 | 0.730 |
Why?
|
| Biomedical Research | 2 | 2023 | 256 | 0.720 |
Why?
|
| Feasibility Studies | 6 | 2022 | 525 | 0.710 |
Why?
|
| Triage | 2 | 2021 | 109 | 0.700 |
Why?
|
| Opiate Substitution Treatment | 2 | 2020 | 187 | 0.700 |
Why?
|
| Pain Management | 2 | 2024 | 146 | 0.700 |
Why?
|
| Diazepam | 1 | 2020 | 10 | 0.700 |
Why?
|
| Calcium | 1 | 2024 | 555 | 0.690 |
Why?
|
| Fentanyl | 4 | 2024 | 72 | 0.690 |
Why?
|
| Patient Care | 1 | 2021 | 78 | 0.690 |
Why?
|
| Medicine | 1 | 2020 | 56 | 0.690 |
Why?
|
| Tenofovir | 2 | 2020 | 8 | 0.680 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 20 | 0.680 |
Why?
|
| Group Processes | 1 | 2020 | 41 | 0.670 |
Why?
|
| Financing, Government | 1 | 2020 | 30 | 0.670 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 412 | 0.670 |
Why?
|
| Cannabidiol | 3 | 2024 | 6 | 0.660 |
Why?
|
| Toilet Facilities | 1 | 2019 | 3 | 0.650 |
Why?
|
| Buprenorphine | 2 | 2020 | 181 | 0.650 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 105 | 0.650 |
Why?
|
| Rilpivirine | 1 | 2019 | 1 | 0.640 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 111 | 0.640 |
Why?
|
| Tuberculosis | 1 | 2022 | 270 | 0.630 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 127 | 0.630 |
Why?
|
| Remote Consultation | 2 | 2016 | 18 | 0.620 |
Why?
|
| Pilot Projects | 6 | 2024 | 914 | 0.620 |
Why?
|
| Poisoning | 2 | 2016 | 31 | 0.620 |
Why?
|
| Efficiency | 1 | 2018 | 37 | 0.600 |
Why?
|
| Pain Threshold | 4 | 2024 | 25 | 0.600 |
Why?
|
| Writing | 1 | 2018 | 41 | 0.590 |
Why?
|
| Medical Informatics Applications | 1 | 2017 | 14 | 0.580 |
Why?
|
| Copper Sulfate | 1 | 2017 | 3 | 0.570 |
Why?
|
| Emergency Medicine | 1 | 2020 | 181 | 0.570 |
Why?
|
| Chelation Therapy | 1 | 2017 | 4 | 0.570 |
Why?
|
| Stomach Diseases | 1 | 2017 | 10 | 0.560 |
Why?
|
| Accidents | 1 | 2017 | 14 | 0.560 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 166 | 0.560 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 51 | 0.560 |
Why?
|
| Prospective Studies | 10 | 2024 | 3067 | 0.560 |
Why?
|
| Coloring Agents | 1 | 2017 | 53 | 0.550 |
Why?
|
| Biomarkers | 2 | 2021 | 1306 | 0.540 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 5 | 0.530 |
Why?
|
| Faculty, Medical | 1 | 2018 | 192 | 0.530 |
Why?
|
| Drug Contamination | 2 | 2017 | 15 | 0.530 |
Why?
|
| Radio Frequency Identification Device | 1 | 2015 | 10 | 0.500 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2016 | 37 | 0.500 |
Why?
|
| Young Adult | 10 | 2024 | 4267 | 0.500 |
Why?
|
| Attitude to Computers | 1 | 2015 | 21 | 0.500 |
Why?
|
| Videoconferencing | 1 | 2015 | 11 | 0.500 |
Why?
|
| Telepathology | 1 | 2015 | 6 | 0.490 |
Why?
|
| Resuscitation | 1 | 2016 | 69 | 0.490 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 312 | 0.490 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2015 | 42 | 0.480 |
Why?
|
| Cocaine | 2 | 2016 | 96 | 0.480 |
Why?
|
| Cell Phone | 1 | 2015 | 42 | 0.470 |
Why?
|
| Skin Diseases | 1 | 2015 | 76 | 0.460 |
Why?
|
| Dermatology | 1 | 2015 | 70 | 0.450 |
Why?
|
| Masks | 3 | 2022 | 20 | 0.440 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 21 | 0.440 |
Why?
|
| Sexual Behavior | 3 | 2024 | 189 | 0.440 |
Why?
|
| Heart Arrest | 1 | 2016 | 161 | 0.440 |
Why?
|
| United States | 14 | 2024 | 7390 | 0.430 |
Why?
|
| Pain Measurement | 5 | 2024 | 327 | 0.430 |
Why?
|
| Equipment Design | 4 | 2020 | 329 | 0.420 |
Why?
|
| Cannabinoids | 2 | 2024 | 38 | 0.420 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 138 | 0.410 |
Why?
|
| Hemorrhage | 1 | 2014 | 260 | 0.390 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 211 | 0.390 |
Why?
|
| Levamisole | 1 | 2011 | 8 | 0.380 |
Why?
|
| Oncologists | 2 | 2022 | 10 | 0.380 |
Why?
|
| Capsules | 3 | 2019 | 34 | 0.380 |
Why?
|
| Electronics | 2 | 2022 | 34 | 0.380 |
Why?
|
| Neutropenia | 1 | 2011 | 62 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 550 | 0.360 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 82 | 0.360 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2373 | 0.350 |
Why?
|
| Aged | 11 | 2024 | 13416 | 0.340 |
Why?
|
| Harm Reduction | 2 | 2020 | 29 | 0.340 |
Why?
|
| Anticoagulants | 1 | 2014 | 477 | 0.330 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2513 | 0.330 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 120 | 0.310 |
Why?
|
| Mobile Applications | 3 | 2020 | 129 | 0.300 |
Why?
|
| Disaster Planning | 2 | 2020 | 48 | 0.300 |
Why?
|
| Adolescent | 7 | 2024 | 5824 | 0.300 |
Why?
|
| Antidotes | 2 | 2020 | 20 | 0.290 |
Why?
|
| Radio Waves | 2 | 2019 | 18 | 0.290 |
Why?
|
| Boston | 3 | 2024 | 246 | 0.280 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 295 | 0.280 |
Why?
|
| Social Stigma | 2 | 2024 | 64 | 0.270 |
Why?
|
| Adenine | 2 | 2024 | 48 | 0.270 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2024 | 141 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2023 | 724 | 0.250 |
Why?
|
| Privacy | 2 | 2022 | 11 | 0.240 |
Why?
|
| Dried Blood Spot Testing | 1 | 2024 | 3 | 0.240 |
Why?
|
| Benzoyl Peroxide | 1 | 2024 | 2 | 0.230 |
Why?
|
| Benzene | 1 | 2024 | 7 | 0.230 |
Why?
|
| Condoms | 1 | 2024 | 47 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5284 | 0.230 |
Why?
|
| Fibromyalgia | 1 | 2024 | 16 | 0.230 |
Why?
|
| Health Personnel | 3 | 2023 | 342 | 0.230 |
Why?
|
| Betacoronavirus | 3 | 2020 | 166 | 0.220 |
Why?
|
| Public Health | 2 | 2022 | 174 | 0.220 |
Why?
|
| Sexual Partners | 1 | 2024 | 75 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 1561 | 0.220 |
Why?
|
| Vasoconstrictor Agents | 1 | 2024 | 64 | 0.210 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 129 | 0.210 |
Why?
|
| Risk-Taking | 1 | 2024 | 158 | 0.210 |
Why?
|
| North Carolina | 2 | 2020 | 68 | 0.210 |
Why?
|
| Awards and Prizes | 1 | 2023 | 33 | 0.210 |
Why?
|
| Administration, Oral | 1 | 2024 | 356 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 147 | 0.210 |
Why?
|
| Armed Conflicts | 1 | 2022 | 3 | 0.210 |
Why?
|
| Weapons | 1 | 2022 | 5 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2024 | 94 | 0.210 |
Why?
|
| Directly Observed Therapy | 1 | 2022 | 3 | 0.200 |
Why?
|
| Computers | 1 | 2022 | 49 | 0.200 |
Why?
|
| Personnel, Hospital | 1 | 2022 | 41 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 55 | 0.200 |
Why?
|
| Warfare | 1 | 2022 | 33 | 0.200 |
Why?
|
| Poisons | 1 | 2022 | 3 | 0.200 |
Why?
|
| Coturnix | 1 | 2022 | 12 | 0.200 |
Why?
|
| Mentoring | 1 | 2023 | 46 | 0.200 |
Why?
|
| Trust | 1 | 2023 | 67 | 0.200 |
Why?
|
| Safety | 1 | 2022 | 142 | 0.200 |
Why?
|
| Chromatography, Liquid | 2 | 2024 | 126 | 0.200 |
Why?
|
| Explosive Agents | 1 | 2022 | 2 | 0.190 |
Why?
|
| Pain Perception | 2 | 2023 | 7 | 0.190 |
Why?
|
| Civil Defense | 1 | 2022 | 12 | 0.190 |
Why?
|
| Hallucinogens | 1 | 2021 | 14 | 0.190 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 76 | 0.190 |
Why?
|
| Anxiety | 1 | 2024 | 387 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2022 | 79 | 0.190 |
Why?
|
| Glucuronides | 1 | 2021 | 11 | 0.190 |
Why?
|
| Communication Barriers | 1 | 2021 | 56 | 0.180 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 85 | 0.180 |
Why?
|
| Phlebotomy | 1 | 2021 | 7 | 0.180 |
Why?
|
| Affect | 2 | 2024 | 123 | 0.180 |
Why?
|
| Publishing | 1 | 2022 | 90 | 0.180 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 127 | 0.180 |
Why?
|
| Chemical Terrorism | 1 | 2020 | 1 | 0.180 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 225 | 0.180 |
Why?
|
| Silicone Elastomers | 1 | 2020 | 2 | 0.180 |
Why?
|
| Physical Examination | 1 | 2021 | 104 | 0.180 |
Why?
|
| Terrorism | 1 | 2020 | 16 | 0.170 |
Why?
|
| Catheterization | 1 | 2021 | 111 | 0.170 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 13 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 14 | 0.170 |
Why?
|
| Phenotype | 1 | 2024 | 1137 | 0.170 |
Why?
|
| Solid Phase Extraction | 1 | 2020 | 9 | 0.170 |
Why?
|
| Professional Role | 1 | 2020 | 38 | 0.170 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 56 | 0.170 |
Why?
|
| Urban Health | 1 | 2020 | 40 | 0.170 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 7 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 19 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2020 | 56 | 0.160 |
Why?
|
| Diffusion of Innovation | 2 | 2017 | 56 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 149 | 0.160 |
Why?
|
| Mouth Mucosa | 1 | 2019 | 24 | 0.160 |
Why?
|
| Emtricitabine, Rilpivirine, Tenofovir Drug Combination | 1 | 2019 | 1 | 0.160 |
Why?
|
| Editorial Policies | 1 | 2020 | 52 | 0.160 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 16 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1025 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 66 | 0.160 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2018 | 12 | 0.150 |
Why?
|
| Methamphetamine | 1 | 2018 | 22 | 0.150 |
Why?
|
| Narcotics | 1 | 2018 | 50 | 0.150 |
Why?
|
| Research Support as Topic | 1 | 2018 | 39 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 470 | 0.140 |
Why?
|
| Heroin Dependence | 1 | 2017 | 22 | 0.140 |
Why?
|
| Methadone | 1 | 2018 | 127 | 0.140 |
Why?
|
| Heroin | 1 | 2017 | 12 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 271 | 0.140 |
Why?
|
| Systems Integration | 1 | 2017 | 26 | 0.140 |
Why?
|
| Saliva | 1 | 2017 | 99 | 0.140 |
Why?
|
| Glass | 1 | 2017 | 21 | 0.140 |
Why?
|
| Transducers | 1 | 2017 | 26 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 116 | 0.140 |
Why?
|
| Aircraft | 1 | 2017 | 18 | 0.140 |
Why?
|
| Emergency Responders | 1 | 2017 | 11 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
| Tissue Engineering | 2 | 2009 | 134 | 0.130 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 30 | 0.130 |
Why?
|
| Machine Learning | 1 | 2018 | 153 | 0.130 |
Why?
|
| Physicians | 2 | 2020 | 435 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 355 | 0.130 |
Why?
|
| RNA, Viral | 3 | 2022 | 259 | 0.130 |
Why?
|
| Point-of-Care Testing | 1 | 2016 | 44 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1118 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2015 | 21 | 0.130 |
Why?
|
| Gelatin | 1 | 2015 | 29 | 0.130 |
Why?
|
| Video Recording | 1 | 2016 | 126 | 0.130 |
Why?
|
| Viral Load | 3 | 2023 | 220 | 0.120 |
Why?
|
| Social Support | 1 | 2018 | 355 | 0.120 |
Why?
|
| Confidentiality | 1 | 2015 | 52 | 0.120 |
Why?
|
| Eyeglasses | 1 | 2015 | 7 | 0.120 |
Why?
|
| Poison Control Centers | 1 | 2014 | 6 | 0.120 |
Why?
|
| Self Report | 1 | 2017 | 359 | 0.120 |
Why?
|
| Industry | 1 | 2014 | 59 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 574 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6071 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2017 | 326 | 0.110 |
Why?
|
| Medical Informatics | 1 | 2014 | 67 | 0.110 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 13 | 0.110 |
Why?
|
| Vitamin K | 1 | 2014 | 14 | 0.110 |
Why?
|
| Research Design | 1 | 2017 | 555 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 255 | 0.110 |
Why?
|
| Limit of Detection | 2 | 2024 | 43 | 0.100 |
Why?
|
| Organophosphates | 2 | 2024 | 16 | 0.100 |
Why?
|
| Legislation, Drug | 2 | 2023 | 17 | 0.100 |
Why?
|
| Rats | 1 | 2016 | 1910 | 0.100 |
Why?
|
| Benchmarking | 2 | 2024 | 135 | 0.100 |
Why?
|
| Software | 1 | 2015 | 367 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2011 | 97 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 687 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5128 | 0.090 |
Why?
|
| Motorcycles | 1 | 2010 | 4 | 0.090 |
Why?
|
| Head Protective Devices | 1 | 2010 | 19 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 179 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2010 | 148 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2050 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2015 | 746 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2007 | 141 | 0.060 |
Why?
|
| Hydrogels | 1 | 2007 | 110 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 1 | 2024 | 31 | 0.060 |
Why?
|
| Alanine | 1 | 2024 | 49 | 0.060 |
Why?
|
| Immunoassay | 1 | 2024 | 67 | 0.060 |
Why?
|
| Colorado | 1 | 2023 | 19 | 0.050 |
Why?
|
| Catastrophization | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ukraine | 1 | 2022 | 13 | 0.050 |
Why?
|
| Health Services | 1 | 2023 | 81 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 715 | 0.050 |
Why?
|
| Animals | 2 | 2022 | 19648 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 73 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 153 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 150 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 264 | 0.050 |
Why?
|
| Chloroquine | 1 | 2022 | 50 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 2374 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2021 | 19 | 0.050 |
Why?
|
| Decontamination | 1 | 2021 | 11 | 0.050 |
Why?
|
| Ethanol | 1 | 2024 | 306 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 76 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2021 | 29 | 0.050 |
Why?
|
| Analgesics | 1 | 2021 | 96 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 102 | 0.040 |
Why?
|
| Security Measures | 1 | 2020 | 5 | 0.040 |
Why?
|
| Attitude | 1 | 2021 | 96 | 0.040 |
Why?
|
| Equipment Reuse | 1 | 2020 | 4 | 0.040 |
Why?
|
| Community Pharmacy Services | 1 | 2020 | 13 | 0.040 |
Why?
|
| Sterilization | 1 | 2020 | 15 | 0.040 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 28 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 402 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 184 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 215 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 115 | 0.040 |
Why?
|
| Hair | 1 | 2020 | 78 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 1283 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 238 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 677 | 0.040 |
Why?
|
| Nurses | 1 | 2020 | 102 | 0.040 |
Why?
|
| San Francisco | 1 | 2018 | 10 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 801 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 215 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 63 | 0.040 |
Why?
|
| Urinalysis | 1 | 2017 | 30 | 0.040 |
Why?
|
| Telemetry | 1 | 2017 | 19 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 813 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 546 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 25 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 96 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 112 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 219 | 0.030 |
Why?
|
| New England | 1 | 2017 | 267 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 100 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 342 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 360 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 523 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 976 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 618 | 0.030 |
Why?
|
| Education | 1 | 2010 | 68 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2009 | 18 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2009 | 21 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2009 | 22 | 0.020 |
Why?
|
| Albumins | 1 | 2009 | 34 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 371 | 0.020 |
Why?
|
| Health Education | 1 | 2010 | 182 | 0.020 |
Why?
|
| Alginates | 1 | 2009 | 44 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2007 | 21 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2007 | 26 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 935 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 559 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2093 | 0.010 |
Why?
|